Teva Canada has initiated a recall of certain Teva-Pregabalin 150 mg capsules after routine testing flagged a potential contamination with sertraline. The action targets specific lots of the medication, though the notice does not specify the exact quantities or lot numbers affected. Health authorities have not indicated any reported adverse events at this time. The recall underscores ongoing quality-control measures in the production and distribution of prescription medications. Patients currently taking Teva-Pregabalin 150 mg capsules are advised to check their packaging and contact their pharmacist or healthcare provider for guidance on alternatives or next steps. Teva Canada has not released a timetable for the completion of the recall process or for replacements. Authorities continue to monitor the situation as more information becomes available.
